ES2334953T3 - Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos. - Google Patents

Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos. Download PDF

Info

Publication number: ES2334953T3
Authority: ES; Spain
Prior art keywords: baselineskip; delta; protein; sequence; fragment
Prior art date: 1995-06-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES96924334T

Other languages

English (en)

Spanish (es)

Inventor

David Ish-Horowicz

Domingo M. P. Henrique

Julian H. Lewis

Spyridon Artavanis-Tsakonas

Grace E. Gray

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cancer Research Horizons Ltd

Yale University

Original Assignee

Imperial Cancer Research Technology Ltd

Yale University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-28

Filing date

1996-06-28

Publication date

2010-03-17

1996-06-28 Application filed by Imperial Cancer Research Technology Ltd, Yale University filed Critical Imperial Cancer Research Technology Ltd

2010-03-17 Application granted granted Critical

2010-03-17 Publication of ES2334953T3 publication Critical patent/ES2334953T3/es

2016-06-28 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 190
102000004169 proteins and genes Human genes 0.000 title claims abstract description 105
238000000034 method Methods 0.000 title claims abstract description 61
239000002773 nucleotide Substances 0.000 title claims abstract description 33
241000251539 Vertebrata <Metazoa> Species 0.000 title abstract description 31
150000001413 amino acids Chemical class 0.000 claims abstract description 383
239000012634 fragment Substances 0.000 claims abstract description 97
101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 claims abstract description 82
238000004519 manufacturing process Methods 0.000 claims abstract description 14
230000003834 intracellular effect Effects 0.000 claims abstract description 7
150000007523 nucleic acids Chemical class 0.000 claims description 74
102000039446 nucleic acids Human genes 0.000 claims description 66
108020004707 nucleic acids Proteins 0.000 claims description 66
108010070047 Notch Receptors Proteins 0.000 claims description 33
230000027455 binding Effects 0.000 claims description 32
102000005650 Notch Receptors Human genes 0.000 claims description 31
239000013598 vector Substances 0.000 claims description 31
125000003729 nucleotide group Chemical group 0.000 claims description 30
108091034117 Oligonucleotide Proteins 0.000 claims description 27
230000014509 gene expression Effects 0.000 claims description 25
238000000338 in vitro Methods 0.000 claims description 14
230000000692 anti-sense effect Effects 0.000 claims description 13
239000013604 expression vector Substances 0.000 claims description 10
108020001507 fusion proteins Proteins 0.000 claims description 10
102000037865 fusion proteins Human genes 0.000 claims description 10
230000000295 complement effect Effects 0.000 claims description 9
239000013599 cloning vector Substances 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
230000004048 modification Effects 0.000 claims description 6
238000012986 modification Methods 0.000 claims description 6
125000000539 amino acid group Chemical group 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 3
230000011664 signaling Effects 0.000 claims description 3
101800003838 Epidermal growth factor Proteins 0.000 claims description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
229940116977 epidermal growth factor Drugs 0.000 claims description 2
230000003053 immunization Effects 0.000 claims description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 5
102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
230000001419 dependent effect Effects 0.000 claims 1
238000002405 diagnostic procedure Methods 0.000 abstract description 3
230000001225 therapeutic effect Effects 0.000 abstract description 3
241000269370 Xenopus <genus> Species 0.000 abstract description 2
238000002560 therapeutic procedure Methods 0.000 abstract description 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 description 345
229940024606 amino acid Drugs 0.000 description 345
108090000765 processed proteins & peptides Proteins 0.000 description 141
235000018102 proteins Nutrition 0.000 description 95
108020004414 DNA Proteins 0.000 description 72
210000004027 cell Anatomy 0.000 description 59
101150014361 Delta gene Proteins 0.000 description 32
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 24
108091028043 Nucleic acid sequence Proteins 0.000 description 22
239000002299 complementary DNA Substances 0.000 description 21
229930010555 Inosine Natural products 0.000 description 20
229960003786 inosine Drugs 0.000 description 20
108700041286 delta Proteins 0.000 description 16
238000009396 hybridization Methods 0.000 description 16
238000011161 development Methods 0.000 description 13
230000018109 developmental process Effects 0.000 description 13
108020004999 messenger RNA Proteins 0.000 description 13
230000001272 neurogenic effect Effects 0.000 description 13
239000000523 sample Substances 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 12
230000000694 effects Effects 0.000 description 11
238000012163 sequencing technique Methods 0.000 description 11
238000010367 cloning Methods 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
102100036462 Delta-like protein 1 Human genes 0.000 description 9
101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 9
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
108091008146 restriction endonucleases Proteins 0.000 description 9
241000894007 species Species 0.000 description 9
238000013519 translation Methods 0.000 description 9
108020004511 Recombinant DNA Proteins 0.000 description 8
241000700605 Viruses Species 0.000 description 8
238000003556 assay Methods 0.000 description 8
239000013615 primer Substances 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 7
108010036039 Serrate-Jagged Proteins Proteins 0.000 description 7
102000011842 Serrate-Jagged Proteins Human genes 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000005714 functional activity Effects 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
238000002965 ELISA Methods 0.000 description 6
241000287828 Gallus gallus Species 0.000 description 6
102100033237 Pro-epidermal growth factor Human genes 0.000 description 6
230000002776 aggregation Effects 0.000 description 6
238000004220 aggregation Methods 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000013459 approach Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000001537 neural effect Effects 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
241000238631 Hexapoda Species 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
238000003018 immunoassay Methods 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
239000000126 substance Substances 0.000 description 5
241000972773 Aulopiformes Species 0.000 description 4
229920001917 Ficoll Polymers 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
239000000853 adhesive Substances 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
230000029087 digestion Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000004766 neurogenesis Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
235000019515 salmon Nutrition 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
102000006601 Thymidine Kinase Human genes 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
239000000074 antisense oligonucleotide Substances 0.000 description 3
238000012230 antisense oligonucleotides Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000008614 cellular interaction Effects 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000023886 lateral inhibition Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000010004 neural pathway Effects 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
238000007899 nucleic acid hybridization Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000003259 recombinant expression Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101000614095 Homo sapiens Proton-activated chloride channel Proteins 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
241001467552 Mycobacterium bovis BCG Species 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
-1 N6-adenine Chemical compound 0.000 description 2
102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 2
108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
241000282887 Suidae Species 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
102100026966 Thrombomodulin Human genes 0.000 description 2
108010079274 Thrombomodulin Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000007818 agglutination assay Methods 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000005094 computer simulation Methods 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
108700023159 delta Opioid Receptors Proteins 0.000 description 2
102000048124 delta Opioid Receptors Human genes 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
230000013020 embryo development Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000000869 mutational effect Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
210000002729 polyribosome Anatomy 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
238000012916 structural analysis Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
241000244203 Caenorhabditis elegans Species 0.000 description 1
101100510615 Caenorhabditis elegans lag-2 gene Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010001515 Galectin 4 Proteins 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
101000801209 Homo sapiens Transducin-like enhancer protein 4 Proteins 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
108091007369 NEUR proteins Proteins 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102100033763 Transducin-like enhancer protein 4 Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000010267 cellular communication Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008011 embryonic death Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
230000008622 extracellular signaling Effects 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
238000012817 gel-diffusion technique Methods 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000003017 in situ immunoassay Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
210000004216 mammary stem cell Anatomy 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
108010065781 myosin light chain 2 Proteins 0.000 description 1
XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
210000001020 neural plate Anatomy 0.000 description 1
210000000276 neural tube Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
108010079892 phosphoglycerol kinase Proteins 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
230000000243 photosynthetic effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000013197 protein A assay Methods 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000010076 replication Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000002023 somite Anatomy 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000002381 testicular Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Diabetes (AREA)
Psychology (AREA)
Cell Biology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES96924334T 1995-06-28 1996-06-28 Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos. Expired - Lifetime ES2334953T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58995P	1995-06-28	1995-06-28
US589P		1995-06-28

Publications (1)

Publication Number	Publication Date
ES2334953T3 true ES2334953T3 (es)	2010-03-17

Family

ID=21692156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES96924334T Expired - Lifetime ES2334953T3 (es)	1995-06-28	1996-06-28	Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos.

Country Status (11)

Country	Link
US (5)	US6262025B1 (2)
EP (1)	EP0861261B9 (2)
JP (3)	JPH11508771A (2)
AT (1)	ATE442373T1 (2)
AU (1)	AU723939B2 (2)
CA (1)	CA2226087C (2)
DE (1)	DE69638023D1 (2)
DK (1)	DK0861261T3 (2)
ES (1)	ES2334953T3 (2)
PT (1)	PT861261E (2)
WO (1)	WO1997001571A1 (2)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050112121A1 (en) *	1992-04-30	2005-05-26	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
AU723939B2 (en)	1995-06-28	2000-09-07	Imperial Cancer Research Technology Ltd	Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US20050158859A1 (en) *	1995-09-29	2005-07-21	Yale University	Manipulation of non-terminally differentiated cells using the Notch pathway
US5780300A (en) *	1995-09-29	1998-07-14	Yale University	Manipulation of non-terminally differentiated cells using the notch pathway
ATE319827T1 (de)	1995-11-17	2006-03-15	Asahi Chemical Ind	Polypeptid, das die differenzierung unterdrueckt
US6887475B1 (en)	1996-11-07	2005-05-03	Lorantis Limited	Notch
JP2001521382A (ja) *	1997-04-04	2001-11-06	ミレニウムファーマスーティカルズインコーポレイテッド	新規なヒトデルタ３組成物ならびにそれらの治療および診断への使用方法
US20060122373A1 (en)	1997-04-04	2006-06-08	Millennium Pharmaceuticals, Inc.	Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6121045A (en) *	1997-04-04	2000-09-19	Millennium Biotherapeutics, Inc.	Human Delta3 nucleic acid molecules
WO1998051799A1 (en) *	1997-05-14	1998-11-19	Asahi Kasei Kogyo Kabushiki Kaisha	Novel differentiation inhibitor
NZ501873A (en) *	1997-06-18	2002-02-01	Zymogenetics Inc	Mammalian neuro-growth factor like protein
US6692919B1 (en)	1997-07-23	2004-02-17	Yale University	Activated forms of notch and methods based thereon
US6436650B1 (en)	1997-07-23	2002-08-20	Yale University	Activated forms of notch and methods based thereon
JP2002520007A (ja) *	1998-07-13	2002-07-09	イエールユニバーシティー	Ｄｅｌｔａ切断産物およびそれに基づく方法
WO2000006726A2 (en) *	1998-07-27	2000-02-10	Amgen Inc.	Delta-related polypeptides
CA2343353A1 (en) *	1998-09-18	2000-03-30	Hyseq, Inc.	Methods and compositions relating to egf-repeat-containing polypeptides
EP1518930B1 (en) *	1998-10-13	2007-05-30	Genentech, Inc.	Methods and compositions for inhibiting neoplastic cell growth
US8084258B2 (en) *	1999-07-12	2011-12-27	University Of Basel	Manipulation of tissue of organ type using the notch pathway
GB9927328D0 (en)	1999-11-18	2000-01-12	Lorantis Ltd	Immunotherapy
US8044259B2 (en)	2000-08-03	2011-10-25	The Regents Of The University Of Michigan	Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en)	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
US20080194022A1 (en) *	2000-08-03	2008-08-14	Clarke Michael F	Isolation and use of solid tumor stem cells
US20020151487A1 (en) *	2000-08-31	2002-10-17	Loyola University Chicago	Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
GB0118155D0 (en)	2001-07-25	2001-09-19	Lorantis Ltd	Superantigen
JP2004537314A (ja) *	2001-07-25	2004-12-16	ロランティスリミテッド	ノッチシグナル伝達モジュレーターを検出する方法
WO2003042246A2 (en) *	2001-11-14	2003-05-22	Lorantis Limited	Inhibitors of the notch signalling pathway for use in the treatment of cancer
CA2497226A1 (en) *	2002-09-10	2004-03-25	Lorantis Limited	Pharmaceutical compositions and medical treatments comprising notch ligand proteins
GB0300428D0 (en) *	2003-01-09	2003-02-05	Lorantis Ltd	Medical treatment
GB0307472D0 (en) *	2003-04-01	2003-05-07	Lorantis Ltd	Medical treatment
CA2528669A1 (en) *	2003-06-09	2005-01-20	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
EP1654383A1 (en) *	2003-08-08	2006-05-10	Licentia, Ltd.	Materials and methods for colorectal cancer screening, diagnosis, and therapy
US20070099209A1 (en) *	2005-06-13	2007-05-03	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
WO2007028110A2 (en) *	2005-09-01	2007-03-08	Vasgene Therapeutics, Inc.	Methods for using and identifying modulators of delta-like 4
US7906116B2 (en)	2005-09-01	2011-03-15	Parkash Gill	Methods for using and identifying modulators of Delta-like 4
US7723112B2 (en)	2005-10-31	2010-05-25	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
EP2511298B1 (en)	2005-10-31	2019-01-16	Oncomed Pharmaceuticals, Inc.	Compositions and Methods for Treating Cancer based on human FZD receptors
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
HUE028379T2 (en) *	2006-09-29	2016-12-28	Oncomed Pharm Inc	Preparations and procedures for the diagnosis and treatment of cancer
RU2448979C2 (ru) *	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
WO2008092002A2 (en)	2007-01-24	2008-07-31	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing pancreatic cancer
TWI506037B (zh)	2008-09-26	2015-11-01	Oncomed Pharm Inc	捲曲結合劑類及彼等之用途
US8883145B2 (en)	2009-10-16	2014-11-11	Oncomed Pharmaceuticals, Inc.	Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
CA2782299A1 (en) *	2009-12-01	2011-06-09	Oncomed Pharmaceuticals, Inc.	Methods for treating cancers comprising k-ras mutations
TWI535445B (zh)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Ｗｎｔ拮抗劑及治療和篩選方法
WO2011123785A2 (en)	2010-04-01	2011-10-06	Oncomed Pharmaceuticals, Inc.	Frizzled-binding agents and uses thereof
US20130095080A1 (en)	2010-04-09	2013-04-18	Fred Hutchinson Cancer Reserach Center	Compositions and methods for providing hematopoietic function
US20130095079A1 (en)	2010-04-09	2013-04-18	Fred Hutchinson Cancer Research Center	Compositions and methods for providing hematopoietic function without hla matching
US8551479B2 (en)	2010-09-10	2013-10-08	Oncomed Pharmaceuticals, Inc.	Methods for treating melanoma
SI3485903T1 (sl)	2011-09-23	2023-02-28	Mereo Biopharma 5, Inc.	Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
EP2788476B1 (en)	2011-12-08	2019-05-22	Fred Hutchinson Cancer Research Center	Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
KR20150014439A (ko) *	2012-03-29	2015-02-06	로버트 제이 플레밍	노치 활성을 조절하기 위한 방법 및 조성물
EP2911691B1 (en)	2012-10-23	2018-10-10	OncoMed Pharmaceuticals, Inc.	Methods of treating neuroendocrine tumors using wnt pathway-binding agents
US9599620B2 (en)	2012-10-31	2017-03-21	Oncomed Pharmaceuticals, Inc.	Methods and monitoring of treatment with a DLL4 antagonist
EP2943566A1 (en)	2013-01-08	2015-11-18	Fred Hutchinson Cancer Research Center	Compositions and methods for expansion of embryonic hematopoietic stem cells
JP2016510411A (ja)	2013-02-04	2016-04-07	オンコメッドファーマシューティカルズインコーポレイテッド	Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en)	2013-03-14	2015-10-27	Oncomed Pharmaceuticals, Inc.	MET-binding agents and uses thereof
AU2014342020C1 (en)	2013-10-31	2019-09-05	Fred Hutchinson Cancer Research Center	Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
US20160176962A1 (en)	2014-10-31	2016-06-23	Oncomed Pharmaceuticals, Inc.	Combination Therapy For Treatment Of Disease
JP6734283B2 (ja)	2015-01-21	2020-08-05	フレッドハッチンソンキャンサーリサーチセンター	遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム
WO2016176652A2 (en)	2015-04-29	2016-11-03	Fred Hutchinson Cancer Research Center	Modified stem cells and uses thereof
JP6985934B2 (ja)	2015-04-29	2021-12-22	フレッドハッチンソンキャンサーリサーチセンター	操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
ES2968074T3 (es)	2015-09-23	2024-05-07	Mereo Biopharma 5 Inc	Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4889818A (en)	1986-08-22	1989-12-26	Cetus Corporation	Purified thermostable enzyme
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5116742A (en)	1986-12-03	1992-05-26	University Patents, Inc.	RNA ribozyme restriction endoribonucleases and methods
US4795699A (en)	1987-01-14	1989-01-03	President And Fellows Of Harvard College	T7 DNA polymerase
IL101728A (en)	1991-05-03	2007-08-19	Univ Yale	Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en)	1991-05-03	2003-11-12	Indiana University Foundation	Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5856441A (en)	1991-05-03	1999-01-05	Yale University	Serrate fragments and derivatives
WO1993012141A1 (en)	1991-12-11	1993-06-24	Yale University	Nucleotide and protein sequences of the serrate gene and methods based thereon
US6004924A (en) *	1991-12-11	1999-12-21	Imperial Cancer Research Technology, Ltd.	Protein sequences of serrate gene products
US5869282A (en)	1991-12-11	1999-02-09	Imperial Cancer Research Technology, Ltd.	Nucleotide and protein sequences of the serrate gene and methods based thereon
US5786158A (en) *	1992-04-30	1998-07-28	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) *	1992-04-30	2005-05-26	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
AU5168393A (en)	1992-09-30	1994-04-26	Yale University	Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
US5750652A (en)	1994-01-21	1998-05-12	Yale University	Deltex proteins
AU723939B2 (en) *	1995-06-28	2000-09-07	Imperial Cancer Research Technology Ltd	Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5780300A (en) *	1995-09-29	1998-07-14	Yale University	Manipulation of non-terminally differentiated cells using the notch pathway
US20050158859A1 (en) *	1995-09-29	2005-07-21	Yale University	Manipulation of non-terminally differentiated cells using the Notch pathway
ATE319827T1 (de)	1995-11-17	2006-03-15	Asahi Chemical Ind	Polypeptid, das die differenzierung unterdrueckt
CA2238404A1 (en)	1995-11-22	1997-05-29	Yale University	Vertebrate deltex proteins, nucleic acids, and antibodies, and related methods and compositions
AU720890B2 (en)	1996-05-31	2000-06-15	National American Red Cross, The	Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
WO1998017793A1 (en)	1996-10-21	1998-04-30	Hsc Research And Development Limited Partnership	Fringe proteins and notch signalling
EP0942998B1 (en)	1996-11-07	2005-07-06	Lorantis Limited	Notch
US20020010137A1 (en) *	1997-09-18	2002-01-24	Genentech, Inc.	Methods and compositions for inhibiting neoplastic cell growth
US6121045A (en) *	1997-04-04	2000-09-19	Millennium Biotherapeutics, Inc.	Human Delta3 nucleic acid molecules
JP2001521382A (ja)	1997-04-04	2001-11-06	ミレニウムファーマスーティカルズインコーポレイテッド	新規なヒトデルタ３組成物ならびにそれらの治療および診断への使用方法
WO1998051799A1 (en)	1997-05-14	1998-11-19	Asahi Kasei Kogyo Kabushiki Kaisha	Novel differentiation inhibitor
US6436650B1 (en) *	1997-07-23	2002-08-20	Yale University	Activated forms of notch and methods based thereon
US6692919B1 (en) *	1997-07-23	2004-02-17	Yale University	Activated forms of notch and methods based thereon
TW406393B (en) *	1997-12-01	2000-09-21	United Microelectronics Corp	Method of manufacturing dielectrics and the inner-lining
JP2002520007A (ja)	1998-07-13	2002-07-09	イエールユニバーシティー	Ｄｅｌｔａ切断産物およびそれに基づく方法
US8084258B2 (en) *	1999-07-12	2011-12-27	University Of Basel	Manipulation of tissue of organ type using the notch pathway
WO2002059285A1 (en)	2000-10-27	2002-08-01	Fred Hutchinson Cancer Research Center	Methods for immortalizing cells
US20070003893A1 (en) *	2005-06-30	2007-01-04	Radek Bures	Combination lighter and breath freshener dispenser

1996
- 1996-06-28 AU AU64817/96A patent/AU723939B2/en not_active Expired
- 1996-06-28 WO PCT/US1996/011178 patent/WO1997001571A1/en not_active Ceased
- 1996-06-28 DE DE69638023T patent/DE69638023D1/de not_active Expired - Lifetime
- 1996-06-28 PT PT96924334T patent/PT861261E/pt unknown
- 1996-06-28 AT AT96924334T patent/ATE442373T1/de active
- 1996-06-28 US US08/981,392 patent/US6262025B1/en not_active Expired - Lifetime
- 1996-06-28 CA CA2226087A patent/CA2226087C/en not_active Expired - Lifetime
- 1996-06-28 JP JP9504614A patent/JPH11508771A/ja not_active Withdrawn
- 1996-06-28 DK DK96924334T patent/DK0861261T3/da active
- 1996-06-28 EP EP96924334A patent/EP0861261B9/en not_active Expired - Lifetime
- 1996-06-28 ES ES96924334T patent/ES2334953T3/es not_active Expired - Lifetime
2001
- 2001-02-15 US US09/783,931 patent/US7118890B2/en not_active Expired - Fee Related
- 2001-07-17 US US09/908,322 patent/US6783956B2/en not_active Expired - Fee Related
2006
- 2006-07-24 US US11/492,497 patent/US7928071B2/en not_active Expired - Fee Related
- 2006-10-10 US US11/546,583 patent/US8415303B2/en not_active Expired - Fee Related
2008
- 2008-07-09 JP JP2008179448A patent/JP2009039101A/ja not_active Withdrawn
2011
- 2011-10-04 JP JP2011220536A patent/JP2012070735A/ja active Pending

Also Published As

Publication number	Publication date
US7928071B2 (en)	2011-04-19
DE69638023D1 (de)	2009-10-22
WO1997001571A1 (en)	1997-01-16
US6262025B1 (en)	2001-07-17
JP2009039101A (ja)	2009-02-26
CA2226087C (en)	2012-01-31
ATE442373T1 (de)	2009-09-15
JPH11508771A (ja)	1999-08-03
US20070082846A1 (en)	2007-04-12
PT861261E (pt)	2009-12-16
DK0861261T3 (da)	2009-12-14
EP0861261A4 (en)	2001-08-29
US20020107194A1 (en)	2002-08-08
EP0861261A1 (en)	1998-09-02
CA2226087A1 (en)	1997-01-16
US20070134239A1 (en)	2007-06-14
EP0861261B9 (en)	2010-02-24
US20030073620A1 (en)	2003-04-17
EP0861261B1 (en)	2009-09-09
JP2012070735A (ja)	2012-04-12
US8415303B2 (en)	2013-04-09
US6783956B2 (en)	2004-08-31
US7118890B2 (en)	2006-10-10
AU6481796A (en)	1997-01-30
AU723939B2 (en)	2000-09-07

Publication	Publication Date	Title
EP0861261B1 (en)	2009-09-09	Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
ES2333384T3 (es)	2010-02-19	Secuencias nucleotidos y proteinas de genes serrate de vertebrados y metodos basados en las mismas.
AU774367B2 (en)	2004-06-24	Nucleotide and protein sequences of nogo genes and methods based thereon
FI121366B (fi)	2010-10-29	Uusia siiliperäisiä polypeptidejä
O'Connell et al.	1995	Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine deaminase
TW302369B (2)	1997-04-11
JPH10510709A (ja)	1998-10-20	摂食行動を変える方法、該方法に有用な化合物、および視床下部の異型神経ペプチドｙ／ペプチドｙｙ受容体（ｙ５）をコードするｄｎａ
JP2002514055A (ja)	2002-05-14	ガラニンｇａｌｒ３受容体をコードするｄｎａおよびその使用
CA2291754C (en)	2009-11-17	Smad-interacting polypeptides and their use
JPH08502168A (ja)	1996-03-12	ニューロン細胞においてイオンチャンネル誘導活性をもつ栄養因子
Crackower et al.	1999	Cloning and characterization of two cytoplasmic dynein intermediate chain genes in mouse and human
WO1997046678A9 (en)	1998-04-16	Nucleic acids and polypeptides related to presenilin
JP2001514487A (ja)	2001-09-11	酸性感受性哺乳動物ニュ−ロン陽イオンチャンネル、そのクロ−ニングおよびその用途
US5470966A (en)	1995-11-28	Neural α-catenin
US20030232336A1 (en)	2003-12-18	Novel human ion channel and transporter family members
US20020082210A1 (en)	2002-06-27	56201, a novel human sodium ion channel family member and uses thereof
CA2251603A1 (en)	1997-10-16	Gene family associated with neurosensory defects
US20030113841A1 (en)	2003-06-19	8105, a novel human sugar transporter family member and uses thereof
US20030096305A1 (en)	2003-05-22	Novel human membrane-associated protein and cell surface protein family members
US20030129625A1 (en)	2003-07-10	Methods of using 5433, a human calcium channel family member
Zerucha	2001	Evolution of auto- and cross-regulatory elements of members of the distal-less-related family of homeobox-containing genes.
US20020076753A1 (en)	2002-06-20	31939, a novel human leucine-rich repeat family member and uses thereof
JPH0466595A (ja)	1992-03-02	哺乳動物ｇａｐ―４３組成物および使用方法
US20020081657A1 (en)	2002-06-27	21784, a novel human calcium channel family member and uses thereof
US20020076752A1 (en)	2002-06-20	33395, a novel human leucine-rich repeat family member and uses thereof